TELESTA THERAPEUTICS INC T.TST

Douglas Loe in Septemer

[sometoast]

Euro Pacific Canada analyst Doug Loe Our model assumes that Telestas now-published (in Journal of Urology) 129-patient single-arm open-label pivotal Phase III BCG-refractory non-muscle-invasive bladder cancer (NMIBC) study was sufficiently robust, and demonstrated sufficiently significant disease-free survival, to justify recommending formal FDA approval.

[DamnYankees]

Im not even sure the Adcomm panel was grasping the application for MCNA. There seemed to be an undercurrent of opposition from the start of the discussion. I'm not convinced that the risk/benefit question was the apex of the decision for many voters. I sensed a pre determined NO without truly weighing the intended question. It matters not at this point but having a US pharma partner might